Guidant's Acculink Is Exclusive CREST Stent; Trial Begins in Six Months
This article was originally published in The Gray Sheet
Executive Summary
Guidant has the option of evaluating an emboli protection device along with its Acculink self-expanding carotid stent in the 2,500-patient Carotid Revascularization Endarterectomy Stenting Trial (CREST), according to study investigators.
You may also be interested in...
J&J Polishes SAPPHIRE Carotid Trial For HCFA Conditional Coverage Appraisal
Johnson & Johnson Cordis plans to submit an investigational device exemption application to FDA in March or April for the SAPPHIRE carotid stent trial, as discussions continue with the Health Care Financing Administration to secure reimbursement coverage.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.